Thursday, 13 December 2012
Tuesday, 11 December 2012
Good news for India Industrial production growth hits 8.2% in October
Industrial production growth rate bounced back to a 16-month high of 8.2 per cent in October on good performance of the manufacturing, power sector and higher output ofcapital as well as consumer goods, indicating sudden recovery in the economy.
The factory output, as measured by the Index of Industrial Production (IIP), contracted by 5 per cent in October last year. The IIP had expanded by 9.5 per cent in June 2011.
Industrial output growth inthe April-October period this fiscal, however, was 1.2 per cent, less than 3.6 per cent in the same period in 2011-12, according to the official data released here today.
Meanwhile, the contraction in the industrial productionduring September this yearwas revised downward to 0.7 per cent per cent from earlier provisional estimates of 0.4 per cent released lastmonth.
The manufacturing sector, which constitutes over 75 per cent of the index, grewby robust 9.6 per cent in October, as against a contraction of 6 per cent in same month last year.
However, the output of the key sector remained low at one per cent in April-October this year as against 3.8 per cent growth in the same period in 2011-12.
Capital goods output also shown remarkable improvement as it grew by 7.5 per cent in October, as against a massive contraction of 26.5 per centin October 2011.
However, output of capital goods contracted in the April-October period by 11.4 per cent, as against a dip in production by 0.5 per cent in the 2011-12 period.
The factory output, as measured by the Index of Industrial Production (IIP), contracted by 5 per cent in October last year. The IIP had expanded by 9.5 per cent in June 2011.
Industrial output growth inthe April-October period this fiscal, however, was 1.2 per cent, less than 3.6 per cent in the same period in 2011-12, according to the official data released here today.
Meanwhile, the contraction in the industrial productionduring September this yearwas revised downward to 0.7 per cent per cent from earlier provisional estimates of 0.4 per cent released lastmonth.
The manufacturing sector, which constitutes over 75 per cent of the index, grewby robust 9.6 per cent in October, as against a contraction of 6 per cent in same month last year.
However, the output of the key sector remained low at one per cent in April-October this year as against 3.8 per cent growth in the same period in 2011-12.
Capital goods output also shown remarkable improvement as it grew by 7.5 per cent in October, as against a massive contraction of 26.5 per centin October 2011.
However, output of capital goods contracted in the April-October period by 11.4 per cent, as against a dip in production by 0.5 per cent in the 2011-12 period.
Merck & Co Asthma drug patents revoked in India following a challenge from Cipla .
In an order, Assistant Controller of Patents & Designs T V Madhusudhan revoked the patent on the ground that it lacked invention.
"The sole process claim also in its entirety is not inventive as the said claim does not describe any inventive feature," the ordersaid.
"In view of the above conclusion I hereby order that the patent bearing number 246328 is revoked," Madhusudhan said in his order.
Schering Corporation, whichwas later acquired by Merck& Co, had applied for patent of the asthma drug inFebruary 2004, and the Indian Patents Office had granted the patent in March2011. Cipla had challenged the patent.
The development is the latest in a series of patent revocations by India's Patent Office.
Last month, the Intellectual Property Appellate Board (IPAB) had turned down drug firm AstraZeneca's plea for a patent on the lung cancer drug Gefitinib.
Similarly, it had also revoked Pfizer's patent on cancer drug 'Sutent'. The drug was granted a patent in India in 2007 but Cipla had opposed it the following year.
Earlier during the year, India Patents Office had invoked compulsory licensing permitting the Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a price, over 30 times lower than charged by its patent-holder Bayer Corporation.
"The sole process claim also in its entirety is not inventive as the said claim does not describe any inventive feature," the ordersaid.
"In view of the above conclusion I hereby order that the patent bearing number 246328 is revoked," Madhusudhan said in his order.
Schering Corporation, whichwas later acquired by Merck& Co, had applied for patent of the asthma drug inFebruary 2004, and the Indian Patents Office had granted the patent in March2011. Cipla had challenged the patent.
The development is the latest in a series of patent revocations by India's Patent Office.
Last month, the Intellectual Property Appellate Board (IPAB) had turned down drug firm AstraZeneca's plea for a patent on the lung cancer drug Gefitinib.
Similarly, it had also revoked Pfizer's patent on cancer drug 'Sutent'. The drug was granted a patent in India in 2007 but Cipla had opposed it the following year.
Earlier during the year, India Patents Office had invoked compulsory licensing permitting the Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a price, over 30 times lower than charged by its patent-holder Bayer Corporation.
Investor Relations
A corporate function, combining finance, marketing and communications, to provide investors with accurate information about a company's performance andprospects.
IPO Financing
The dollar value of initial public offering (IPO) securities issued in accordance with a TSX or TSX Venture Exchange approved transaction. It is the stated prospectus price multiplied by "the number of securities issued under the IPO plus the over allotment".
Issue
Any of a company's securities or the act of distributing the securities. Issued shares refer to the portion of a company's shares that have been issued for sale. A company does not have to issue the total number of its authorized shares.
Investment Fund
A closed-end fund that offers investors the ability to buy a security that represents a portfolio of investments with a specific investment strategy. These products use funds raised through a public offering to invest in a portfolio of securities, which are activelymanaged to create income streams for investors, typically through a combination of dividends, capital gains, interest payments, and in some cases, income from derivative investment strategies. These funds are not directly related to an operating business. Some examples are: funds of income funds, senior loan funds, mortgage-backed security funds, and commodity funds.
Investment Dealer
Securities firms that employ investment advisors to work with retail and institutional clients. Investment dealers have underwriting, trading and research departments.
Investment Counsellor
A specialist in the investment industry paid byfee to provide advice and research to investors with large accounts.
Investment Capital
Initial investment capital necessary for starting a business. Investment capital usually consists of inventory,equipment, pre-opening expenses and leaseholds.
Subscribe to:
Posts (Atom)